L Pyroglutamic Acid
Background
Section titled “Background”L-pyroglutamic acid, also known as 5-oxoproline, is a cyclic derivative of glutamic acid, a common amino acid. It serves as an intermediate in the gamma-glutamyl cycle, a metabolic pathway crucial for the synthesis and breakdown of glutathione, as well as for the transport of amino acids across cell membranes. Unlike glutamic acid, l-pyroglutamic acid is not incorporated into proteins.
Biological Basis
Section titled “Biological Basis”The biological formation of l-pyroglutamic acid typically occurs from glutamic acid or gamma-glutamyl cysteine. Its involvement in the gamma-glutamyl cycle is vital for maintaining appropriate cellular glutathione levels, which are essential for antioxidant defense. Disruptions in this cycle can lead to imbalances in amino acid metabolism. Genetic studies have identified variations that influence metabolic pathways, including those involved in amino acid interconversion. For instance, a polymorphism in thePARK2 gene, rs992037 , has been observed to alter the concentrations of several amino acids, some of which are directly connected to the urea cycle.[1]This suggests that genetic factors can play a role in the complex interactions of amino acids, including those related to glutamate and its derivatives like l-pyroglutamic acid. ThePARK2gene encodes parkin, a ubiquitin ligase, and its functional role in degradation supports its impact on metabolic pathways involving amino acid interconversion.[1]
Clinical Relevance
Section titled “Clinical Relevance”Imbalances in l-pyroglutamic acid levels can have clinical implications. Elevated levels may indicate pyroglutamic acidemia, a rare metabolic disorder that can be either acquired or inherited, often linked to glutathione synthetase deficiency. This condition can lead to severe metabolic acidosis. Given the genetic influences on amino acid metabolism, as demonstrated by studies linkingPARK2gene polymorphisms to altered amino acid concentrations, understanding the genetic regulation of l-pyroglutamic acid may offer insights into various metabolic disturbances.[1]Such genetic associations with metabolite profiles can highlight candidate single nucleotide polymorphisms (SNPs) that are linked to relevant medical phenotypes.[1]
Social Importance
Section titled “Social Importance”The investigation of l-pyroglutamic acid and its genetic associations is socially important as it contributes to a deeper understanding of human metabolism and disease. Identifying genetic variants that affect amino acid levels, particularly those related to glutamate and the urea cycle, can assist in predicting an individual’s susceptibility to specific metabolic conditions.[1]This knowledge has the potential to inform personalized medicine strategies, allowing for earlier diagnosis, targeted interventions, and improved management for individuals at risk of metabolic disorders. Furthermore, comprehending the broader impact of genetic variations on metabolite profiles can provide new insights into the functional basis of various medical conditions and their underlying biological mechanisms.[1]
Limitations
Section titled “Limitations”Methodological and Statistical Constraints
Section titled “Methodological and Statistical Constraints”Research into complex traits, such as l pyroglutamic acid levels, often faces limitations inherent in genome-wide association studies (GWAS) design. Many studies, especially early ones, may have been limited by moderate sample sizes, which can reduce statistical power to detect genetic associations with modest effect sizes.[2] This can lead to false negative findings, where true associations are missed, or conversely, moderately strong associations might represent false positives, particularly without independent replication. [3] The extensive multiple testing inherent in GWAS also presents a significant challenge in distinguishing true signals from chance findings, necessitating stringent significance thresholds and external validation. [4]
Furthermore, the scope of genetic variation interrogated in some GWAS might be incomplete due to reliance on specific genotyping arrays or older HapMap builds, potentially missing causal variants not captured by the available SNPs. [5] While imputation helps to address this, the quality of imputation can vary, and some variants might remain unassessed. Meta-analyses, while increasing power, can be affected by heterogeneity across studies, which may arise from differences in population demographics, genotyping platforms, or analytical methods. [6] The reliance on fixed-effects models in some meta-analyses might not fully capture such underlying heterogeneity, impacting the robustness of combined effect estimates. [6] The statistical handling of non-normally distributed phenotypes through transformations also introduces variability, as different transformation methods can influence association statistics. [7]
Generalizability and Phenotypic Assessment Challenges
Section titled “Generalizability and Phenotypic Assessment Challenges”A significant limitation in many genetic studies is the restricted diversity of the study populations, often predominantly of European ancestry. [8] This inherent bias limits the generalizability of findings to other ethnic groups, as genetic architecture and allele frequencies can differ substantially across populations. [3] While efforts are made to control for population stratification, residual effects could still influence association results, particularly in heterogeneous cohorts. [9]
Phenotypic assessment also presents challenges that can impact the interpretation of genetic associations. Variability in biomarker levels can arise from subtle differences in assay methodologies and demographic characteristics across studies, making direct comparisons difficult. [6]The use of proxy measures or indicators for complex traits, such as TSH for thyroid function or cystatin C for kidney function, may not fully capture the underlying biological construct or disease state, potentially obscuring more direct genetic influences.[3] Although averaging multiple observations for a phenotype can reduce measurement noise, it might also mask dynamic physiological changes or individual-level variability that could be relevant to genetic effects. [10]
Unaccounted Variability and Future Research Directions
Section titled “Unaccounted Variability and Future Research Directions”Current GWAS often focus on identifying single genetic variants with additive effects, but they frequently do not account for complex gene-environment interactions, which can significantly modulate phenotypic expression. [2]Environmental factors, diet, lifestyle, and other genetic modifiers can influence how a specific genotype translates into a phenotype, and their omission in analyses represents a substantial knowledge gap. For instance, the impact of genetic variants on certain traits, such as associations ofACE and AGTR2with left ventricular mass, has been shown to vary with dietary salt intake, highlighting the importance of considering such contextual factors.[2]
Furthermore, despite the identification of numerous genetic loci, a considerable proportion of the heritability for many complex traits remains unexplained. The identified variants typically account for only a fraction of the total phenotypic variance, suggesting that many other genetic factors, including rare variants, structural variations, or complex epistatic interactions, are yet to be discovered. [11] Moving forward, comprehensive functional follow-up studies are crucial to elucidate the biological mechanisms by which associated genetic variants influence traits. GWAS data, while powerful for discovery, are often insufficient for a comprehensive understanding of candidate genes or their precise regulatory roles, necessitating further targeted investigations. [4]
Variants
Section titled “Variants”The OPLAH gene encodes for pyroglutamyl-peptidase I, an enzyme essential for the hydrolysis of pyroglutamic acid (pGlu) from the N-terminus of peptides and proteins. This enzymatic activity plays a crucial role in protein degradation and recycling pathways, preventing the undue accumulation of pyroglutamic acid in the body. The variant rs3935209 is located within the OPLAH gene, and its presence may influence the efficiency or expression of this enzyme, thereby potentially affecting metabolic profiles and overall health.. [1] Understanding how genetic variants like rs3935209 affect enzyme activity is a key objective of genome-wide association studies, which aim to link genetic differences to various metabolic traits and disease susceptibility.[12]
L-pyroglutamic acid, also known as 5-oxoproline, is a cyclic amino acid that is typically present at low concentrations in human plasma. WhenOPLAHenzyme function is compromised, L-pyroglutamic acid can accumulate, leading to a metabolic condition known as pyroglutamic acidosis or 5-oxoprolinuria. This disorder can manifest with symptoms such as high anion gap metabolic acidosis, central nervous system dysfunction, and hemolytic anemia, especially in individuals with certain genetic predispositions or exposures to specific drugs. The enzyme’s role in maintaining the proper balance of this metabolite is therefore critical for preventing systemic metabolic disturbances..[1] Genetic variations influencing metabolic pathways are frequently investigated in studies exploring biomarkers for various diseases and their underlying mechanisms. [6]
While the specific functional consequences of rs3935209 on OPLAHactivity or L-pyroglutamic acid levels require further dedicated investigation, its location within the gene suggests a potential role in modulating the enzyme’s efficiency. Variants within coding regions can alter the resulting protein’s structure and function, while those in regulatory regions might affect the gene’s expression levels. Ifrs3935209 leads to reduced OPLAH activity, it could contribute to an increased risk of pyroglutamic acid accumulation, particularly under conditions of metabolic stress or in combination with other genetic or environmental factors.. [1] Understanding such genetic influences is crucial for the development of personalized medicine approaches, where individual genetic profiles could inform risk assessment and guide therapeutic strategies for metabolic conditions. [13]
There is no information about ‘l pyroglutamic acid’ in the provided context.
Key Variants
Section titled “Key Variants”Signs and Symptoms
Section titled “Signs and Symptoms”Biochemical Assessment and Detection
Section titled “Biochemical Assessment and Detection”L-pyroglutamic acid is a metabolite whose levels in human serum are assessed through targeted metabolite profiling.[1] The primary measurement approach involves electrospray ionization (ESI) tandem mass spectrometry (MS/MS), a quantitative metabolomics platform that allows for precise determination of its concentration. [1] This diagnostic tool provides a functional readout of the body’s physiological state, contributing to a comprehensive understanding of an individual’s metabolomic profile. [1] Sample preparation for these measurements typically includes obtaining serum from blood, which involves coagulation and centrifugation, followed by deep freezing until the analytical process can be performed. [1]
Research Role and Potential Clinical Correlations
Section titled “Research Role and Potential Clinical Correlations”While specific clinical signs or symptoms directly associated with varying levels of L-pyroglutamic acid are not detailed, its measurement plays a significant role in genome-wide association studies (GWAS).[1]These studies utilize L-pyroglutamic acid as a metabolic trait to identify genetic variants that influence its plasma concentrations.[1] The overarching goal is to link these metabolic profiles to broader “medical phenotypes,” thereby offering new insights into the functional background of human genetic variation. [1]The identification of genetic loci associated with L-pyroglutamic acid levels could serve as prognostic indicators or contribute to differential diagnoses in future clinical applications, by revealing underlying physiological mechanisms.
Causes of L-Pyroglutamic Acid
Section titled “Causes of L-Pyroglutamic Acid”Genetic Predisposition in Amino Acid Metabolism
Section titled “Genetic Predisposition in Amino Acid Metabolism”Genetic variations represent a primary factor influencing the circulating levels of metabolites, including those involved in the L-pyroglutamic acid pathway. A notable example is the polymorphismrs992037 within the PARK2 gene, which has been identified to significantly alter the concentrations of several amino acids in human serum. This PARK2variant is understood to impact a metabolic pathway that specifically involves glutamate, among other amino acids, suggesting its role in amino acid interconversion and degradation processes.[1]Given that L-pyroglutamic acid is a cyclic derivative directly formed from glutamate, these genetic influences on glutamate metabolism and amino acid flux are highly likely to consequently affect the availability and levels of L-pyroglutamic acid in the body.
Biological Background
Section titled “Biological Background”Metabolic Regulation and Homeostasis
Section titled “Metabolic Regulation and Homeostasis”The field of metabolomics comprehensively measures endogenous metabolites within biological fluids, offering a functional snapshot of an individual’s physiological state. Genetic variations can significantly impact the dynamic balance, or homeostasis, of crucial metabolites such as lipids, carbohydrates, and amino acids in the human body. [1]These variations can modulate metabolic pathways, leading to distinct metabolite profiles in serum that reflect underlying genetic predispositions. For instance, the plasma levels of liver enzymes, key indicators of hepatic metabolic function, are influenced by genetic factors, as demonstrated by studies identifying chromosomal regions regulating enzymes like alkaline phosphatase 2 (Akp2) activity. [6]
Genetic Influence on Biomolecule Levels
Section titled “Genetic Influence on Biomolecule Levels”The fundamental principle of molecular genetics dictates that DNA is transcribed into RNA, which is then translated into proteins, with alterations at any stage potentially affecting biological function and disease susceptibility.[7] Genome-wide association studies have identified DNA variants, termed expression quantitative trait loci (eQTLs), that influence mRNA expression levels, and protein quantitative trait loci (pQTLs), which affect the abundance of specific proteins in the blood. For example, common variants in or near genes such as IL6R, CCL4, IL18, LPA, GGT1, SHBG, CRP, and IL1RN have been associated with circulating levels of their respective protein products. [7] These genetic influences can manifest through various mechanisms, including altered gene transcription rates, modifications in the cleavage of bound versus unbound soluble receptors, changes in protein secretion rates, or variations in gene copy number. [7] Furthermore, alternative splicing of pre-mRNA, a crucial regulatory mechanism, allows a single gene to produce multiple protein isoforms with potentially different functions, as seen with exon 13 of HMGCR and the APOB mRNA, impacting protein activity and cellular processes. [14]
Enzymatic Pathways and Cellular Function
Section titled “Enzymatic Pathways and Cellular Function”Enzymes play central roles in facilitating metabolic reactions and maintaining cellular integrity. Genetic variations can modulate the activity of critical enzymes, thereby influencing overall metabolic health. For instance, gamma-glutamyltransferase (GGT1), a liver enzyme, is subject to genetic regulation that impacts its plasma activity. [7] Similarly, 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), a rate-limiting enzyme in the mevalonate pathway, is crucial for cholesterol synthesis, and its activity and degradation are influenced by factors such as alternative splicing and oligomerization state. [14] Beyond metabolic enzymes, specific transporters like SLC2A9are vital for cellular function, influencing the movement of metabolites such as uric acid across membranes and affecting its serum concentration and excretion.[15] Other key biomolecules, including apolipoproteins like APOC3 and APOB, are essential components of lipoproteins, and their levels are critical for lipid transport and metabolism. [16]
Systemic Effects and Pathophysiological Relevance
Section titled “Systemic Effects and Pathophysiological Relevance”Disruptions in metabolic pathways and the regulation of key biomolecules can have profound systemic consequences, contributing to various pathophysiological processes and diseases. Elevated plasma levels of liver enzymes, such as gamma-glutamyltransferase, are linked to an increased risk of nonalcoholic fatty liver disease, type 2 diabetes mellitus, and cardiovascular disease.[6] Genetic variants influencing lipid metabolism genes, including LPA, HMGCR, APOC3, ANGPTL3, and ANGPTL4, are associated with dyslipidemia, altered LDL-cholesterol levels, and an increased risk of coronary artery disease.[7]Moreover, variations in the urate transporterSLC2A9are directly implicated in conditions like gout due to their impact on serum uric acid concentrations.[15]These metabolic and genetic factors can exert organ-specific effects, particularly on the liver and cardiovascular system, leading to homeostatic disruptions and contributing to the development and progression of complex human diseases.[6]
Pathways and Mechanisms
Section titled “Pathways and Mechanisms”Metabolic Regulation and Lipid Homeostasis
Section titled “Metabolic Regulation and Lipid Homeostasis”Genetic variations can profoundly influence complex metabolic networks, particularly those governing lipid homeostasis and energy metabolism. The mevalonate pathway, crucial for cholesterol biosynthesis, is tightly regulated by enzymes such as 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR). This enzyme’s activity is a key control point in isoprenoid and adenosylcobalamin metabolism, with its regulation involving proteins like SREBP-2. [17] Furthermore, genes like FADS1 and FADS2 within a specific gene cluster are associated with the composition of fatty acids in phospholipids, highlighting the genetic underpinnings of lipid profiles. [18]
Beyond biosynthesis, lipid catabolism and transport are also under genetic control, with genes such as ANGPTL3 and ANGPTL4 playing roles in regulating lipid metabolism. [19]Adiponutrin, another important player, has its gene expression regulated by insulin and glucose in human adipose tissue, and variations in this gene are associated with obesity.[20] Studies have also identified associations between genetic polymorphisms in LIPC and phosphatidylethanolamines, suggesting an impact on the cholesterol pathway. [1]
Amino Acid and Urate Metabolism
Section titled “Amino Acid and Urate Metabolism”The intricate balance of amino acid metabolism and the urea cycle are subject to genetic regulation, impacting various physiological states. For instance, a polymorphism in thePARK2 gene (rs992037 ) has been observed to alter the concentrations of several amino acids, some of which are directly connected to the urea cycle.[1] PARK2encodes parkin, a ubiquitin ligase, and its functional role in degradation supports the concept of amino acid interconversion being affected by this genetic variant.[1]
Urate metabolism, critical for maintaining serum uric acid levels, is significantly influenced by specific transporters. TheSLC2A9gene encodes a facilitative glucose transporter (GLUT9) that also functions as a renal urate anion exchanger, thereby regulating blood urate levels and influencing serum uric acid concentrations.[21]Dysregulation of this transporter can contribute to conditions like gout.[15] Additionally, gamma-glutamyltransferase (GGT), a liver enzyme, serves as a significant biomarker, with its plasma levels influenced by genetic regions such as the Akp2 gene. [6]
Gene Regulation and Protein Modification
Section titled “Gene Regulation and Protein Modification”Gene expression and protein function are meticulously controlled through various regulatory mechanisms, including transcriptional, post-transcriptional, and post-translational processes. Alternative splicing is a key regulatory mechanism that allows a single gene to produce multiple protein isoforms, as demonstrated by common single nucleotide polymorphisms (SNPs) inHMGCR affecting the alternative splicing of exon 13. [14]This process, crucial for generating protein diversity, is implicated in numerous biological functions and can be a factor in human disease.[22]
Transcription factor regulation plays a central role in controlling gene expression. For example, transcription factors like HNF1Aare involved in metabolic-syndrome pathways and can influence the expression of genes such as C-reactive protein.[23] Post-translational modifications, such as ubiquitination, are essential for protein degradation and functional modulation; PARK2, encoding a ubiquitin ligase, exemplifies how such modifications can impact amino acid metabolism and contribute to disease when dysfunctional.[1]Thyroid hormone receptors also exhibit differential interactions with proteins depending on the presence or absence of thyroid hormone, highlighting another layer of regulatory complexity.[24]
Systems-Level Integration and Disease Mechanisms
Section titled “Systems-Level Integration and Disease Mechanisms”Biological systems operate through highly integrated networks where various pathways crosstalk and influence each other, leading to emergent properties and often revealing disease-relevant mechanisms. Metabolomics studies highlight how genetic variants can associate with changes in metabolite homeostasis, providing intermediate phenotypes that bridge genotype and complex clinical outcomes.[1]For instance, associations between polymorphisms and phospholipids can point to causal links with diseases like type 2 diabetes, bipolar disorder, and rheumatoid arthritis.[1]
Pathway dysregulation is a common theme in disease etiology. Loss-of-function mutations in thePARK2gene, a ubiquitin ligase, are linked to Parkinson’s disease through their impact on amino acid metabolism.[1] Similarly, variations in genes like GCKR and HNF1A are part of metabolic-syndrome pathways, influencing conditions such as type 2 diabetes. [23]Other examples include the association of glycosylphosphatidylinositol-specific phospholipase D with nonalcoholic fatty liver disease[25] and the influence of MEF2C and PRKAG2in cardiac morphogenesis and function, with their dysregulation potentially leading to conditions like dilated cardiomyopathy.[26] The activation of the mitogen-activated protein kinase (MAPK) pathway is another crucial signaling cascade involved in various cellular responses. [27]
References
Section titled “References”[1] Gieger C., et al. “Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum.”PLoS Genet., vol. 4, no. 11, 2008, p. e1000282.
[2] Vasan, Ramachandran S., et al. “Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study.”BMC Med Genet, vol. 8, 2007, p. 57.
[3] Hwang, Shih-Jen, et al. “A genome-wide association for kidney function and endocrine-related traits in the NHLBI’s Framingham Heart Study.” BMC Medical Genetics, vol. 8, 2007.
[4] Benjamin, Emelia J., et al. “Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study.”BMC Med Genet, vol. 8, 2007, p. 57.
[5] Yang, Qiong, et al. “Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study.”BMC Medical Genetics, vol. 8, 2007.
[6] Yuan X., et al. “Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes.” Am J Hum Genet., vol. 82, no. 1, 2008, pp. 139-149.
[7] Melzer, David, et al. “A genome-wide association study identifies protein quantitative trait loci (pQTLs).” PLoS Genet, vol. 4, no. 5, 2008, e1000072.
[8] Ferrucci, Luigi, et al. “Common variation in the beta-carotene 15,15’-monooxygenase 1 gene affects circulating levels of carotenoids: a genome-wide association study.” The American Journal of Human Genetics, vol. 84, no. 2, 2009, pp. 125-33.
[9] Pare, Guillaume, et al. “Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6,578 women.” PLoS Genetics, vol. 4, no. 7, 2008, e1000118.
[10] Benyamin, Beben, et al. “Variants in TF and HFE explain approximately 40% of genetic variation in serum-transferrin levels.”The American Journal of Human Genetics, vol. 83, no. 6, 2008, pp. 687-92.
[11] Kathiresan, Sekar, et al. “Common variants at 30 loci contribute to polygenic dyslipidemia.” Nat Genet, vol. 41, no. 1, 2009, pp. 56-65.
[12] Wallace C., et al. “Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia.”Am J Hum Genet., vol. 82, no. 1, 2008, pp. 139-149.
[13] Willer CJ., et al. “Newly identified loci that influence lipid concentrations and risk of coronary artery disease.”Nat Genet., vol. 40, no. 1, 2008, pp. 161-169.
[14] Burkhardt, R. et al. “Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13.” Arterioscler Thromb Vasc Biol, 2008.
[15] Vitart, V. et al. “SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout.”Nat Genet, 2008.
[16] Pollin, T. I., et al. “A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection.” Science, vol. 326, no. 5957, 2009, pp. 993-996.
[17] Goldstein, J.L. and Brown, M.S. “Regulation of the mevalonate pathway.” Nature, 1990.
[18] Schaeffer, L. et al. “Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids.” Hum Mol Genet, 2006.
[19] Koishi, R. et al. “Angptl3 regulates lipid metabolism in mice.” Nat Genet, 2002.
[20] Moldes, M. et al. “Adiponutrin gene is regulated by insulin and glu-cose in human adipose tissue.”Eur. J. Endocrinol., 2006.
[21] Döring, A. et al. “SLC2A9 influences uric acid concentrations with pronounced sex-specific effects.”Nat Genet, 2008.
[22] Caceres, J.F. and Kornblihtt, A.R. “Alternative splicing: multiple control mechanisms and involvement in human disease.”Trends Genet, 2002.
[23] Ridker, P.M. et al. “Loci related to metabolic-syndrome pathways including LEPR,HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women’s Genome Health Study.”Am J Hum Genet, 2008.
[24] Lee, D.H. et al. “Serum gamma-glutamyltransferase predicts non-fatal myocardial infarction and fatal coronary heart disease among 28,838 middle-aged men and women.”Eur. Heart J., 2006.
[25] Chalasani, N. et al. “Glycosylphosphatidylinositol-specific phospholipase d in nonalcoholic Fatty liver disease: A preliminary study.”J. Clin. Endocrinol. Metab., 2006.
[26] Lin, Q. et al. “Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C.” Science, 1997.
[27] Williamson, D. et al. “Mitogen-activated protein kinase (MAPK) pathway activation: effects of age and acute exercise on human skeletal muscle.”J Appl Physiol, 2001.